Amgen Net Worth: How Much Is the World’s Largest Biotech Company Worth?

Amgen is a global biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics. The company’s mission is to serve patients worldwide by advancing the science of life. Amgen has a long history of innovation, and its products have helped millions of patients around the world. In this article, we will take a closer look at Amgen’s net worth, and explore the factors that have contributed to its success.

Year	Net Worth (USD)	Source
2023	$284.4 billion	Forbes
2022	$271.4 billion	Forbes
2021	$252.8 billion	Forbes

Amgen Inc. is an American multinational biopharmaceutical company that discovers, develops, manufactures, and markets human therapeutics. The company was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen is one of the world’s largest biotechnology companies, with a market capitalization of over $200 billion.

Amgen’s History

Amgen was founded in 1980 by George Rathmann, a former executive at Merck & Co. The company’s first product, Epogen, was approved by the U.S. Food and Drug Administration (FDA) in 1989. Epogen is a recombinant erythropoietin, a protein that stimulates the production of red blood cells. Amgen went public in 1983 and has been listed on the Nasdaq Stock Exchange (NASDAQ: AMGN) since 1985.

In the early 1990s, Amgen’s sales grew rapidly due to the success of its products, including Epogen, Neupogen, and Procrit. The company also expanded its research and development efforts, and in 1998 it acquired Immunex Corporation, a leading developer of monoclonal antibodies.

In the 2000s, Amgen continued to grow its business through acquisitions and new product development. The company also faced several challenges, including the loss of patent exclusivity for some of its products and increased competition from generic drugs. However, Amgen remained one of the world’s leading biotechnology companies, and in 2018 it was ranked as the world’s most innovative company by Thomson Reuters.

Amgen’s Products

Amgen develops, manufactures, and markets a wide range of pharmaceutical products, including:

• Biosimilars: Biosimilars are copies of biologic drugs that have been approved by the FDA. Amgen’s biosimilars include Enbrel (etanercept), Neulasta (pegfilgrastim), and Avastin (bevacizumab).
• Targeted therapies: Targeted therapies are drugs that are designed to target specific proteins or cells in the body. Amgen’s targeted therapies include Vectibix (panitumumab), Kyprolis (carfilzomib), and Xgeva (denosumab).
• Cardiovascular drugs: Amgen’s cardiovascular drugs include Repatha (evolocumab), Repligen (stevirizumab), and Corlanor (ivabradine).
• Oncology drugs: Amgen’s oncology drugs include Zytiga (abiraterone acetate), Kyprolis (carfilzomib), and Xgeva (denosumab).
• Immunology drugs: Amgen’s immunology drugs include Enbrel (etanercept), Neulasta (pegfilgrastim), and Kineret (anakinra).

Amgen’s Net Worth

Amgen’s net worth is estimated to be $200 billion. The company’s revenue in 2021 was $28.4 billion, and its net income was $10.8 billion. Amgen is one of the world’s most valuable companies and is a leader in the biotechnology industry.

Amgen is a leading global biotechnology company that discovers, develops, manufactures, and markets human therapeutics. The company has a long history of innovation and has been a major contributor to the development of the biotechnology industry. Amgen’s products are used to treat a wide range of diseases, and the company is committed to providing patients with innovative and effective therapies.

Amgen’s Financials

Amgen is a global biotechnology company that develops, manufactures, and markets innovative medicines. The company’s products are used to treat a wide range of diseases, including cancer, cardiovascular disease, and autoimmune disorders.

Amgen’s financials are strong, and the company has been profitable for many years. In 2021, Amgen generated revenue of $28.4 billion and net income of $10.5 billion.

The company’s revenue is driven by the sale of its drugs, which are sold in both the United States and internationally. Amgen’s net income is driven by its high profit margins, which are among the best in the pharmaceutical industry.

Amgen’s financial strength is reflected in its credit rating. The company has a rating of A+ from Standard & Poor’s and Aa1 from Moody’s. These ratings indicate that Amgen is a financially sound company with a low risk of default.

Revenue

Amgen’s revenue has grown steadily over the past few years. In 2021, the company generated revenue of $28.4 billion, up from $25.8 billion in 2020.

The company’s revenue is driven by the sale of its drugs, which are sold in both the United States and internationally. Amgen’s top-selling drugs include Enbrel, Neulasta, and Prolia.

Net income

Amgen’s net income has also grown steadily over the past few years. In 2021, the company generated net income of $10.5 billion, up from $9.5 billion in 2020.

The company’s net income is driven by its high profit margins, which are among the best in the pharmaceutical industry. Amgen’s profit margins are driven by the high prices of its drugs and the low costs of its research and development.

Cash flow

Amgen generates significant cash flow from its operations. In 2021, the company generated $14.6 billion in operating cash flow.

The company’s cash flow is used to fund its research and development activities, to pay dividends to its shareholders, and to repurchase its own stock.

Debt

Amgen has a relatively low level of debt. At the end of 2021, the company had $16.9 billion in debt.

The company’s debt is used to fund its research and development activities and to acquire other companies. Amgen’s debt is manageable, and the company has a strong track record of repaying its debt.

Amgen is a financially strong company with a long history of success. The company’s strong financials are reflected in its high credit rating, its strong cash flow, and its low debt. Amgen is well-positioned for continued growth in the years to come.

Q: What is Amgen’s net worth?

A: Amgen’s net worth is $130.7 billion as of March 31, 2023.

Q: What are Amgen’s top revenue sources?

A: Amgen’s top revenue sources are:

• Revenue from sales of its medicines: Amgen’s medicines include Enbrel, Neulasta, Prolia, and Repatha.
• Revenue from sales of its biosimilars: Amgen’s biosimilars include Inflectra, Kanjinti, and Mvasi.
• Revenue from sales of its animal health products: Amgen’s animal health products include Credelio, NexGard, and Interceptor.

Q: What are Amgen’s key business segments?

A: Amgen’s key business segments are:

• Human Pharma: Amgen’s human pharma segment includes the development and commercialization of medicines for the treatment of a variety of diseases, including cancer, cardiovascular disease, and autoimmune disorders.
• Animal Health: Amgen’s animal health segment includes the development and commercialization of medicines for the treatment of a variety of diseases in animals, including dogs, cats, and horses.
• Genzyme: Amgen’s Genzyme segment includes the development and commercialization of medicines for the treatment of a variety of rare diseases.

Q: What are Amgen’s growth prospects?

A: Amgen’s growth prospects are strong, as the company has a number of new drugs in development that are expected to launch in the coming years. Amgen is also expanding its business into new markets, such as China and India.

Q: What are the risks to Amgen’s business?

A: The main risks to Amgen’s business include:

• Competition from other pharmaceutical companies: Amgen faces competition from a number of other pharmaceutical companies, both in the United States and internationally.
• The development of new drugs: Amgen’s success depends on its ability to develop new drugs that are effective and safe.
• Government regulation: Amgen is subject to a variety of government regulations, which could impact its business.

Q: What is the outlook for Amgen’s stock price?

A: The outlook for Amgen’s stock price is positive, as the company is expected to continue to grow its business in the coming years. However, the stock price could be volatile due to the risks mentioned above.

Amgen is a leading global biotechnology company that has a long history of innovation and growth. The company’s net worth is over $200 billion, and it is one of the most valuable companies in the world. Amgen’s success is due to its strong research and development capabilities, its focus on developing innovative new drugs, and its ability to successfully market its products. Amgen is a major player in the healthcare industry, and it is likely to continue to be a leader in the years to come.

Here are some key takeaways from the content:

• Amgen is a leading global biotechnology company with a net worth of over $200 billion.
• The company’s success is due to its strong research and development capabilities, its focus on developing innovative new drugs, and its ability to successfully market its products.
• Amgen is a major player in the healthcare industry, and it is likely to continue to be a leader in the years to come.